Object. A public competition based on qualifications and interview is open for the assignment of one Research Grant, in accordance to “art. 22, comma 4, letter B” of the Italian law 240/2010 and to the University Regulations for the awarding of research grants issued by Rector’s decree n. 1699, March 31, 2011 and subsequent modifications and additions, as specified below.
Object. The Certificates comprise the following product categories: TWIN-WIN Index Certificates.
Object. 2.1 The Sponsor entrusts the Entity and the Department with the execution of the Clinical Trial under the conditions indicated in this Agreement, in accordance with the Protocol, with any subsequent amendments, as well as with the changes to this Contract / budget deriving from them and formalized through the necessary acts of modification promptly signed.
2.2 The Clinical Trial must be conducted in the most scrupulous compliance with the Protocol, in the current version, accepted by the Principal Investigator and approved by the Ethics Committee and the Competent Authority, in accordance with current legislation on clinical trials of medicinal products and the ethical and deontological principles that inspire the medical activity of the professionals involved in various capacities.
2.3 The Trial must also be conducted in accordance with the principles contained in the Convention on
2.4 Con la sottoscrizione del presente Contratto, le Parti dichiarano di conoscere e accettare il contenuto di quanto sopra richiamato.
2.5 Il Promotore e lo Sperimentatore principale, avendo l’obbligo di tutelare la salute dei pazienti, quando ricorrano le circostanze, possono adottare urgenti e adeguate misure a tutela della sicurezza dei pazienti, quali la sospensione temporanea dello studio (interruzione del trattamento per i pazienti già coinvolti nella sperimentazione, ovvero interruzione dell’inclusione di nuovi soggetti), con le modalità previste dall’art. 38 del Regolamento (UE) n. 536/2014, fermo restando l’obbligo per il Promotore di informare immediatamente il Comitato Etico, l’Autorità Competente ed i Centri di sperimentazione, oltre che i partecipanti allo studio in merito ai nuovi eventi, alle misure intraprese e al programma di provvedimenti da adottare, completando tempestivamente le procedure previste dalla vigente normativa. Il Promotore, avuta comunicazione dallo sperimentatore di un evento avverso grave, comunica tempestivamente alla banca dati elettronica tutte le reazioni sospette avverse gravi e inattese nei termini di cui al comma 2 dell’art. 42 del Regolamento (UE) n. 536/2014, anche ai sensi del comma 3 mediante segnalazione. 2.6 Poiché la Sperimentazione prevede l’inclusione competitiva dei pazienti, è prevista da parte dell’Ente l’inclusione di circa 3 soggetti, con il limite del numero massimo di 142 pazienti candidabili alla Sperimentazione a livello globale e dei termini previsti dal Promotore. Il periodo previsto di inclusione è suscettibile di ...
Object. 2.1 These General Sale Conditions rule the way and the sale conditions of the Products manufactured by Sylcom.
2.2 These are General Sale Conditions, anyway the conditions agreed in each Proforma invoice will be valid only. 2.3The following General Sale Conditions are edited in the web site.
Object. 2.1. Il/La Modello/a conferisce all’Agenzia, in esclusiva, mandato senza rappresentanza, nell’interesse comune delle parti (in rem propriam) ed a titolo oneroso, ai sensi degli artt. 1703 e 1705 c.c., al fine di pro- muovere la propria immagine e di ricercare, negoziare e concludere – nella più ampia autonomia – con terzi soggetti (a titolo esemplificativo: agenzie di pubblicità, aziende ope- ranti direttamente nel settore moda ed affini, società editrici, etc.) rap- porti contrattuali aventi ad oggetto le prestazioni professionali del/la Modello/a e la concessione dei rela- tivi diritti di utilizzazione economica della sua immagine derivanti dalle prestazioni rese.
2.2. Dette prestazioni professionali po- tranno consistere, a titolo esemplifi- cativo, nella realizzazione di servizi fotografici nel settore moda, dell’abbigliamento, ed a questi col- legati; nella partecipazione del/la Modello/aa sfilate, nonché ad ogni altro evento con finalità pubblicita- ria e/o commerciale, artistica o cul- turale.
Object. 2.1. These General Terms and Conditions of Purchase govern the Purchases of Products between the Buyer and the Seller and will be binding if signed by the Seller and in all cases in which the Seller begins to execute an Order of the Seller. In the event of a conflict between the conditions and terms set out in these General Conditions of Purchase and the terms and conditions agreed upon in the individual Purchase, the latter shall prevail.
2.2. The Buyer shall not be bound by the Seller's General Terms and Conditions of Sale, even if they are referred to or contained in acceptances, delivery notes, invoices, or any other documentation produced by the Seller. The GTCS shall not be binding on the Purchaser even as a result of tacit consent.
2.3. These General Terms and Conditions of Purchase replace and extinguish any other agreement with the same object between the Buyer and the Seller.
Object. A selection procedure by qualifications is hereby opened for the assignment of n. 1 departmental research grants with a duration 24 months and for a gross amount of € 55.127,69 (€ 27.563,85/anno)
Object. A subscription is the purchase of a prepaid and non-cumulative credit, consisting of a certain number of trips at a reduced cost (discount). The User may use against payment – if available at the given time – a special FREE NOW offer consisting in purchase of a specified number of electronic codes or one code for a specified number of trips to be used for payments for taxi trips booked through the App (“Subscription”). The Subscription consists in purchase of:
Object. The Certificates are based on an Index, the so called underlying. The Certificates are derivative securities, whose price behaviour depend on that of the Index.
Object. The Sponsor/CRO hereby entrusts to OPBG, which accepts, the task of conducting the Study under the conditions specified below, in accordance with the Protocol and with subsequent amendments approved by the Ethics Committee. The Study shall be conducted in full compliance with the Protocol, in compliance with existing legislation on the subject of observational Study on drugs and medical devices (Circular no 6 of the Ministry of Health of 2(09/2002, AIFA Decision of 20/03/2008 – Guidelines for the classification and carrying out of observational studies on drugs) and where applicable, in compliance with existing legislation on clinical Study on drugs, and in compliance with the ethical principles and codes of professional conduct underpinning medical activities. The Study shall also be conducted in compliance with the principles of the Helsinki Declaration (most recent version), the rules of Good Clinical Practice (M.D. of 15/07/1997 and subsequent amendments ), the Xxxxxx Convention and laws concerning the prevention of corruption. By signing this Agreement, the Parties declare that they are aware of and agree to the content of the documents referred to above. OPBG guarantees it possesses the expertise, instruments, equipment and personnel needed to carry out the Study, and undertakes to see that this Agreement and the Protocol are complied with by all Institution personnel involved in the Study. OPBG guarantees it possesses the expertise, instruments, equipment and staff needed to carry out the Study, with the exception of the following equipment, for which a commodatum between the parties will be entered into in accordance with the provisions of art. 5 herein. OPBG also undertakes to see that this Agreement and the Protocol are complied with by all OPBG’s staff involved in the Study. OPBG undertakes to enrol no. ………. patients within the deadline established by the Protocol. Since the Study entails the competitive enrolment of patients, the number of individuals to be enrolled by OPBG may vary depending on enrolment capacity, the only limit being the maximum allowed number of patients to be enrolled at a global level. Any changes to enrollable patients at OPBG’s O.U. ____________shall be the subject of a written agreement between the Parties, and shall be reported to the OPBG’s Ethics Committee. OPBG shall keep all Study-related documentation for a period of 7 (seven) years from the date of completion of the Study. At the request of the Sponsor/CRO, and a...